NZ599839A - Synergistic antiviral composition and use thereof - Google Patents
Synergistic antiviral composition and use thereofInfo
- Publication number
- NZ599839A NZ599839A NZ599839A NZ59983910A NZ599839A NZ 599839 A NZ599839 A NZ 599839A NZ 599839 A NZ599839 A NZ 599839A NZ 59983910 A NZ59983910 A NZ 59983910A NZ 599839 A NZ599839 A NZ 599839A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antiviral composition
- synergistic antiviral
- neuraminidase inhibitor
- laninamivir
- peramivir
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 title 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 abstract 2
- 239000002911 sialidase inhibitor Substances 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 abstract 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229950004244 laninamivir Drugs 0.000 abstract 1
- 229960003752 oseltamivir Drugs 0.000 abstract 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 abstract 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 abstract 1
- 229960001084 peramivir Drugs 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 229960001028 zanamivir Drugs 0.000 abstract 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical group CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28214809P | 2009-12-22 | 2009-12-22 | |
| PCT/EP2010/007726 WO2011076367A2 (en) | 2009-12-22 | 2010-12-17 | Synergistic antiviral composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599839A true NZ599839A (en) | 2014-02-28 |
Family
ID=44063696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599839A NZ599839A (en) | 2009-12-22 | 2010-12-17 | Synergistic antiviral composition and use thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10022449B2 (enExample) |
| EP (1) | EP2515889B1 (enExample) |
| JP (1) | JP5902628B2 (enExample) |
| KR (1) | KR101862415B1 (enExample) |
| CN (1) | CN102652017A (enExample) |
| AU (1) | AU2010335594B2 (enExample) |
| BR (1) | BR112012015202B1 (enExample) |
| CA (1) | CA2779532C (enExample) |
| CL (1) | CL2012001695A1 (enExample) |
| DK (1) | DK2515889T3 (enExample) |
| EA (1) | EA022840B1 (enExample) |
| ES (1) | ES2531367T3 (enExample) |
| IL (1) | IL219552A (enExample) |
| MX (1) | MX2012007166A (enExample) |
| NZ (1) | NZ599839A (enExample) |
| PL (1) | PL2515889T3 (enExample) |
| PT (1) | PT2515889E (enExample) |
| SG (1) | SG181421A1 (enExample) |
| SI (1) | SI2515889T1 (enExample) |
| WO (1) | WO2011076367A2 (enExample) |
| ZA (1) | ZA201202482B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012126777A1 (en) * | 2011-03-18 | 2012-09-27 | Marinomed Biotechnologie Gmbh | Inhibition of neuraminidase activity |
| RU2469020C1 (ru) * | 2011-11-08 | 2012-12-10 | Александр Васильевич Иващенко | (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения |
| RU2520836C1 (ru) * | 2013-02-27 | 2014-06-27 | Александр Васильевич Иващенко | (3r,4r,5s)-4-амино-5-(2,2-дифторацетиламино)-3-(1-этилпропокси)-циклогекс-1-енкарбоновая кислота и ее эфиры, способ их получения и применения |
| PT2898888T (pt) * | 2014-01-22 | 2019-07-16 | Visufarma B V | Composição que compreende iota-carragenina contra conjuntivite viral |
| US12594285B2 (en) | 2016-02-25 | 2026-04-07 | Applied Biological Laboratories, Inc. | Compositions and methods for protecting against airborne pathogens and irritants |
| EP3419629A4 (en) * | 2016-02-25 | 2019-10-30 | Applied Biological Laboratories, Inc. | COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES |
| US11304989B2 (en) * | 2017-10-06 | 2022-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Peptides for use in the treatment of viral infections |
| WO2019160261A1 (ko) * | 2018-02-14 | 2019-08-22 | (주)나노메디카 | 항바이러스 처리 방법, 항바이러스 필터, 및 이를 구비한 마스크 |
| KR102316819B1 (ko) * | 2018-04-20 | 2021-10-25 | 한미약품 주식회사 | 카라기난을 유효성분으로 포함하는 보존성이 개선된 액상 제제 |
| GB2579600B (en) | 2018-12-05 | 2023-07-05 | Byotrol Plc | Anti-viral composition |
| MX2021016040A (es) * | 2019-07-03 | 2022-03-11 | Aillis Inc | Composicion farmaceutica para el tratamiento de infecciones de virus de influenza. |
| WO2021184123A1 (en) * | 2020-03-18 | 2021-09-23 | Encyt Technologies, Inc. | Compositions and methods for the treatment of coronavirus infection and respiratory compromise |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593314B1 (en) * | 1999-10-19 | 2003-07-15 | Abbott Laboratories | Neuraminidase inhibitors |
| JP2001181188A (ja) * | 1999-12-28 | 2001-07-03 | Marine Biotechnol Inst Co Ltd | インフルエンザウイルス感染阻害剤 |
| SI2101792T1 (sl) | 2006-12-05 | 2010-08-31 | Marinomed Biotechnologie Gmbh | Uporaba karagenana za zdravljenje rinovirusnih infekcij |
| EP1930015A1 (en) * | 2006-12-05 | 2008-06-11 | Marinomed Biotechnologie GmbH | Use of carrageenan for treating rhinovirus infections |
| WO2008147468A2 (en) | 2006-12-18 | 2008-12-04 | Amcol International | Compositions comprising virus-interacting layered phyllosilicates and a therapeutic agent, and methods of use |
| SI2178533T1 (sl) * | 2007-08-24 | 2013-07-31 | Marinomed Biotechnologie Gmbh | Antivirusni sestavek, ki obsega sulfatiran polisaharid: iota-karagenan |
-
2010
- 2010-12-17 AU AU2010335594A patent/AU2010335594B2/en not_active Ceased
- 2010-12-17 EP EP10810910.9A patent/EP2515889B1/en active Active
- 2010-12-17 BR BR112012015202-5A patent/BR112012015202B1/pt active IP Right Grant
- 2010-12-17 NZ NZ599839A patent/NZ599839A/en unknown
- 2010-12-17 CN CN2010800551771A patent/CN102652017A/zh active Pending
- 2010-12-17 SI SI201030883T patent/SI2515889T1/sl unknown
- 2010-12-17 EA EA201290373A patent/EA022840B1/ru unknown
- 2010-12-17 PL PL10810910T patent/PL2515889T3/pl unknown
- 2010-12-17 SG SG2012033643A patent/SG181421A1/en unknown
- 2010-12-17 MX MX2012007166A patent/MX2012007166A/es active IP Right Grant
- 2010-12-17 ES ES10810910T patent/ES2531367T3/es active Active
- 2010-12-17 KR KR1020127016072A patent/KR101862415B1/ko active Active
- 2010-12-17 DK DK10810910.9T patent/DK2515889T3/en active
- 2010-12-17 JP JP2012545143A patent/JP5902628B2/ja active Active
- 2010-12-17 US US13/513,961 patent/US10022449B2/en active Active
- 2010-12-17 PT PT10810910T patent/PT2515889E/pt unknown
- 2010-12-17 CA CA2779532A patent/CA2779532C/en active Active
- 2010-12-17 WO PCT/EP2010/007726 patent/WO2011076367A2/en not_active Ceased
-
2012
- 2012-05-03 IL IL219552A patent/IL219552A/en active IP Right Grant
- 2012-05-04 ZA ZA2012/02482A patent/ZA201202482B/en unknown
- 2012-06-21 CL CL2012001695A patent/CL2012001695A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2515889T3 (en) | 2015-03-02 |
| AU2010335594B2 (en) | 2015-05-21 |
| IL219552A0 (en) | 2012-06-28 |
| AU2010335594A1 (en) | 2012-05-24 |
| CL2012001695A1 (es) | 2013-03-08 |
| ZA201202482B (en) | 2012-12-27 |
| SI2515889T1 (sl) | 2015-04-30 |
| US20120302522A1 (en) | 2012-11-29 |
| WO2011076367A2 (en) | 2011-06-30 |
| PT2515889E (pt) | 2015-03-20 |
| KR20120107970A (ko) | 2012-10-04 |
| SG181421A1 (en) | 2012-07-30 |
| EA022840B1 (ru) | 2016-03-31 |
| CN102652017A (zh) | 2012-08-29 |
| WO2011076367A3 (en) | 2011-09-01 |
| EP2515889A2 (en) | 2012-10-31 |
| JP5902628B2 (ja) | 2016-04-13 |
| KR101862415B1 (ko) | 2018-05-29 |
| BR112012015202A2 (pt) | 2016-04-05 |
| EA201290373A1 (ru) | 2012-11-30 |
| MX2012007166A (es) | 2012-07-23 |
| CA2779532A1 (en) | 2011-06-30 |
| JP2013515022A (ja) | 2013-05-02 |
| EP2515889B1 (en) | 2014-12-10 |
| BR112012015202B1 (pt) | 2020-12-08 |
| IL219552A (en) | 2016-11-30 |
| US10022449B2 (en) | 2018-07-17 |
| CA2779532C (en) | 2018-05-22 |
| PL2515889T3 (pl) | 2015-05-29 |
| ES2531367T3 (es) | 2015-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012007166A (es) | Composicion antiviral sinergica y su uso. | |
| IN2012DN02805A (enExample) | ||
| MX341684B (es) | Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel. | |
| TN2011000370A1 (en) | Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| PH12013501842A1 (en) | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
| IL203448A (en) | History of azabiphenylaminobenzoic acid for use in the treatment or prevention of a pathological condition or disease susceptible to reduction by dhodh inhibition and medicinal preparations containing them | |
| MY159630A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
| PH12013501143A1 (en) | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof | |
| JO3199B1 (ar) | مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها | |
| UA105033C2 (uk) | Фармацевтична композиція, що включає глюкопіранозилзаміщене похідне бензолу, фармацевтична дозована форма, що містить зазначене похідне, їх застосування для лікування метаболічного порушення | |
| MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
| MY157860A (en) | Prevention and treatment of secondary infections following viral infection | |
| GB0625648D0 (en) | Compounds | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| UA107687C2 (ru) | Комбинированная композиция, которая в качестве активных ингредиентов содержит l-карнитин или пропионил-l-карнитин, троксерутин, диосмин и гесперидин, для предотвращения и/или лечения хронических заболеваний вен. | |
| MY173491A (en) | Therapeutic or prophylactic agent for biliary tract diseases | |
| MX2013002261A (es) | N-fenetiltriazolonacetamidas sustituidas y su uso. | |
| TN2010000266A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
| MY151590A (en) | Substituted quinolones iii | |
| WO2010086617A3 (en) | Phosphoantigens for the treatment of burkholderia infections | |
| JO2965B1 (en) | The use of ferroxine in the treatment or prevention of malaria | |
| UA100918C2 (ru) | Мягкая лекарственная форма (мазь) | |
| EA201490935A1 (ru) | Терапевтическая комбинация мемантина и баклофена и содержащая их фармацевтическая композиция | |
| TN2011000008A1 (en) | Use of hdac inhibitors for the treatment of hodgkin's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2015 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20141126 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2016 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20151125 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2017 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20161124 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2018 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20171130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2019 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20181121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2020 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20191127 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2021 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20201204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2022 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20211127 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2023 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20221122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2024 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20231122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 DEC 2025 BY EUROPEAN PATENT ANNUITY SERVICE GMBH Effective date: 20241129 |